# Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

> **NCT00807573** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 44 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00807573
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2015-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807573, "Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00807573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*